Trial Profile
A Randomized, Double Blind, Multi Center, Parallel Study to Evaluate the Efficacy and Safety of Tacrolimus Lipid Tablets (Manufactured By Intas Pharmaceuticals Ltd) Compared to Prograf (Tacrolimus Immediate Release Capsules-Astellas Pharma Canada, Inc) in Adult Patients with Active Rheumatoid Arthritis Who Have Resistance OR Intolerance to DMARDs. - NA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2018
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Intas Pharmaceuticals
- 09 Oct 2017 Status changed from not yet recruiting to completed.
- 02 Sep 2016 New trial record